In addition, EVO directly induces fat loss through an increase in Ppargc1α in white adipose tissue in obese mice23, inhibits vascular inflammation via modulation of Sirt1/NF-κB in atherosclerosis in ApoE−/− mice21, and ameliorates fatty liver by increasing insulin sensitivity22. Here, PPARGC1A is linked to atherosclerosis.